Troy Robinson promoted to managing director of Chugai Pharma Europe

Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him in his current role as managing director of Chugai Pharma UK.

Chugai Pharma Europe (CPE) has promoted Troy Robinson and Mike Crosher into the positions of managing director of CPE and managing director of the firm’s UK subsidiary, Chugai Pharma UK (CPU).

While Robinson will in his new role as managing director of CPE be responsible for all of Chugai’s European business, Crosher will oversee UK commercial operations as he works alongside the firm’s existing business partners to bring products to patients in Ireland and the UK.

Robinson, who started his career in financial services, brings to the role 11 years in pharmaceuticals and fast-moving consumer goods (FMCGs) having served as a member of Chugai Pharma UK’s leadership team since 2012.

While Robinson most recently acted as managing director of CPU, he has held various positions including Head of Corporate Services within CPE and Finance Director for CPU.

Commenting on his own appointment Troy Robinson said:  “I am proud to be able to drive Chugai’s operations forward in this new role at a European level. I am convinced that Europe is a region with huge potential, and our shared expertise uniquely positions us to deliver important medicines to patients across the continent. I look forward to working together with my colleagues in the UK, France and Germany to form new partnerships.”

Mike Crosher, who is currently commercial director at CPU, will thus take on Robinson’s role as he becomes managing director of the UK branch of the firm. Crosher, who began his career as an analytical chemist made his move into the pharmaceutical industry in 2003. He has been in his current role since 2013.

John Halls, who is set to step down from his position as managing director of CPE on 30 September said: “I congratulate both Troy and Mike on their appointments, they will bring a wealth of experience that will drive our ambitions forward both in Europe and the UK.”

Back to listing